– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –
– Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma –
– Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 –
SAN DIEGO, CA, USA I June 13, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually.
“The data being presented today at EAACI continues to demonstrate the potential of rademikibart to deliver best-in-class efficacy for asthma patients,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Building on the previously reported data from our Phase 2b asthma study, these analyses highlight rademikibart’s capability to not only rapidly deliver improvements in lung function, but also significantly reduce annualized asthma exacerbation rates, particularly in those with high eosinophil and fractional exhaled nitric oxide or FeNO counts, key markers of type 2 inflammation. We believe these findings continue to bolster support for our rapid Phase 2 clinical development plan and we look forward to reporting topline data from our parallel Seabreeze STAT studies in the first half of 2026.”
Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma
Abstract Number: 001678
Presenter: Rekha Chaudhuri, M.D.
Session Title: Clinical Trials on Airways Diseases
Date and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST
- Results from the Company’s Phase 2b trial of rademikibart in moderate-to-severe asthma were evaluated in a post-hoc analysis to assess rademikibart’s ability to improve lung function in subgroups of patients with Type 2 inflammation-driven asthma, as indicated by elevated baseline eosinophil counts of ≥150 or ≥300 cells/µL.
- Rademikibart rapidly improved prebronchodilator forced expiratory volume in one second (FEV1) at the first in-clinic assessment at Week 1, which was sustained through 24 weeks of treatment, with greater improvement demonstrated in the elevated baseline eosinophil subgroups than in the overall population.
- In addition to objective lung function, rapid and sustained improvements in patient reported asthma control in the rademikibart treatment groups were also noted, evidenced by increased change from baseline in Asthma Control Questionnaire (ACQ-6) scores in the elevated baseline eosinophil subgroups as compared to placebo.
- Rademikibart treatment groups were associated with substantially lower reports of patients experiencing high post-baseline eosinophil counts compared to published dupilumab data.
- These results demonstrate that rademikibart has the potential to improve lung function in patients with Type 2 inflammation-driven asthma.
Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma
Abstract Number: 001671
Presenter: Rekha Chaudhuri, M.D.
Session Title: Clinical Trials on Airways Diseases
Date and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST
- Results from the Company’s Phase 2b trial of rademikibart in moderate-to-severe asthma were investigated in a post-hoc analysis to determine the annualized asthma exacerbation rate (AAER) in patients with Type 2 inflammation-driven asthma, as indicated by elevated baseline eosinophil counts of ≥150 or ≥300 cells/µL. The analysis also evaluated changes in annualized asthma exacerbation rate based on elevated exhaled nitric oxide (FeNO ≥25 ppb), an additional, independent marker of Type 2 inflammation.
- Rademikibart also achieved clinically meaningful reductions in AAER in subgroups with markers of Type 2 inflammation: 63% in patients with elevated baseline eosinophils, 69% in patients with elevated FeNO, and 74% in patients with elevated baseline eosinophils and elevated FeNO.
- These results highlight rademikibart’s potential to reduce asthma exacerbations, particularly in patients with elevated markers of Type 2 inflammation.
The presentations are available on Connect’s website under the presentations and publications section.
About Connect Biopharma and Rademikibart
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry.
For more information visit www.connectbiopharm.com.
SOURCE: Connect Biopharma
Post Views: 1,707
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –
– Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma –
– Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 –
SAN DIEGO, CA, USA I June 13, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually.
“The data being presented today at EAACI continues to demonstrate the potential of rademikibart to deliver best-in-class efficacy for asthma patients,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Building on the previously reported data from our Phase 2b asthma study, these analyses highlight rademikibart’s capability to not only rapidly deliver improvements in lung function, but also significantly reduce annualized asthma exacerbation rates, particularly in those with high eosinophil and fractional exhaled nitric oxide or FeNO counts, key markers of type 2 inflammation. We believe these findings continue to bolster support for our rapid Phase 2 clinical development plan and we look forward to reporting topline data from our parallel Seabreeze STAT studies in the first half of 2026.”
Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma
Abstract Number: 001678
Presenter: Rekha Chaudhuri, M.D.
Session Title: Clinical Trials on Airways Diseases
Date and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST
- Results from the Company’s Phase 2b trial of rademikibart in moderate-to-severe asthma were evaluated in a post-hoc analysis to assess rademikibart’s ability to improve lung function in subgroups of patients with Type 2 inflammation-driven asthma, as indicated by elevated baseline eosinophil counts of ≥150 or ≥300 cells/µL.
- Rademikibart rapidly improved prebronchodilator forced expiratory volume in one second (FEV1) at the first in-clinic assessment at Week 1, which was sustained through 24 weeks of treatment, with greater improvement demonstrated in the elevated baseline eosinophil subgroups than in the overall population.
- In addition to objective lung function, rapid and sustained improvements in patient reported asthma control in the rademikibart treatment groups were also noted, evidenced by increased change from baseline in Asthma Control Questionnaire (ACQ-6) scores in the elevated baseline eosinophil subgroups as compared to placebo.
- Rademikibart treatment groups were associated with substantially lower reports of patients experiencing high post-baseline eosinophil counts compared to published dupilumab data.
- These results demonstrate that rademikibart has the potential to improve lung function in patients with Type 2 inflammation-driven asthma.
Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma
Abstract Number: 001671
Presenter: Rekha Chaudhuri, M.D.
Session Title: Clinical Trials on Airways Diseases
Date and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST
- Results from the Company’s Phase 2b trial of rademikibart in moderate-to-severe asthma were investigated in a post-hoc analysis to determine the annualized asthma exacerbation rate (AAER) in patients with Type 2 inflammation-driven asthma, as indicated by elevated baseline eosinophil counts of ≥150 or ≥300 cells/µL. The analysis also evaluated changes in annualized asthma exacerbation rate based on elevated exhaled nitric oxide (FeNO ≥25 ppb), an additional, independent marker of Type 2 inflammation.
- Rademikibart also achieved clinically meaningful reductions in AAER in subgroups with markers of Type 2 inflammation: 63% in patients with elevated baseline eosinophils, 69% in patients with elevated FeNO, and 74% in patients with elevated baseline eosinophils and elevated FeNO.
- These results highlight rademikibart’s potential to reduce asthma exacerbations, particularly in patients with elevated markers of Type 2 inflammation.
The presentations are available on Connect’s website under the presentations and publications section.
About Connect Biopharma and Rademikibart
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry.
For more information visit www.connectbiopharm.com.
SOURCE: Connect Biopharma
Post Views: 1,707